The global virology specimen collection market size was valued at USD 5.6 Billion in 2021 and is estimated to experience a negative CAGR of -0.5% during the forecast period of 2022 to 2032.
Growth of the market can be attributed to:
During the COVID-19 pandemic, the growth of the market was stagnated owing to nation wide lockdowns. On the other hand, testing of virus specimens became essential owing to the urgent need for curbing viruses.
Technological advancements in the field of specimen collection have made it easier for exchange of information regarding viruses. As the nature of viruses differ from region to region owing to mutation of the same, the market for virology specimen collection has gained traction.
The outbreak of Zika virus and Babesia alongside announcements for their inclusion in virology specimen collection tests have indicated the need for innovation in virology specimen collection technologies, consumables, and instruments.
Other countries have also undertaken initiatives to check for new and emerging diseases. In addition, the prevalence of EBOLA, Zika virus, SARS-CoV-2, AIDS, flu, and STDs is driving the growth for virology specimen collection market.
| Attributes | Details |
|---|---|
| Virology Specimen Collection Market CAGR (2022 to 2032) | -0.5% |
| Virology Specimen Collection Market (2026) | USD 5.3 Billion |
| Virology Specimen Collection Market Attraction | Innovation in specimen collection devices technologies to keep the global market attractive |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
High awareness levels regarding the disease transmission, diagnosis, and effective management of microbial infections have been observed in North America. In addition, government initiatives to support product development for virology specimen collection is influencing market growth.
In addition, large share of North America in this market can be attributed to the increasing adoption of NAT (due to the high prevalence of TTIs). Furthermore, technological developments including portable diagnostics is favoring the growth of the market.
Growing income levels, greater health awareness, and the rising incidence of lifestyle diseases is contributing to the growth of virology specimen collection market. Currently, ELISA is widely used in India, with NAT registering relatively low penetration.
Emerging markets such as India, the Middle East, and Africa offer promising opportunities for players in the virology specimen collection industry due to their increasing disposable incomes and improving healthcare infrastructure.
NAT is still not mandatory in India, thus, states in India are using NAT in ID-NAT format. For Instance, AIIMS, PGI Chandigarh, CMC Vellore, Medanta-The Medicity, and Narayana Hrudayalaya, are using, and 40 blood banks are using the pooling technique. Similarly, the Indian government is taking initiatives to train doctors, hospitals, and blood banks to use NAT.
On the other hand, regions like US, Canada, most of Europe, Japan, Korea, Singapore, Sri Lanka, UAE, South Africa, Thailand, and China. Almost 100 blood banks are using Nat for virology specimen collection.
The growth virology specimen collection market has stagnated in recent times because of the diverted focus of public healthcare resources towards the detection of widespread coronavirus infections.
The frequent outbreak of viral diseases in different parts of the world has provided the necessary impetus for adopting successful innovations in the virology specimen collection processes and devices. Market players in the high-income countries are at the forefront of taking advantage of these facilities to dominate the global microbiology specimen collection market.
ELISA is a main source for diagnosis because of its affordability, although enhanced sources are still prohibitively expensive, posing a market problem.
In the short term, relying on ELISA is a crucial impediment to the growth of NAT's virology specimen collection market. Due to the high expense of sophisticated testing, earlier, less efficient tests, such as first-generation ELISA, are being used more frequently. Flu, Zika virus, STDs, AIDS, and Ebola virus public awareness campaigns are also a crucial component in raising public knowledge and, as a result, affecting the market growth.
While it is encouraging that new diagnostic techniques are becoming accessible to improve clinical treatment in low-resource settings, the cost of each test is a significant barrier to acceptance and long-term use.
Only giant corporations can afford significant capital expenditures and high R&D and manufacturing costs. New entrants will be unable to enter the market due to this.
The demands a decrease in the cost of microbiology specimen collection products will continue to stifle market expansion until it is met and overcome.
The epidemics of Zika and Babesia and news that they would be included in virology specimen collecting tests highlight the need for new microbiology specimen collection technologies, consumables, and equipment. Other governments have launched their efforts to monitor new and emerging illnesses.
The prevalence of malaria in African countries, collection, transportation, and storage of samples for viral diagnosis and the risk of Zika virus transmission via mosquitos has resulted in regulations for Zika virus screening across the region. Various medium solutions have been suggested for stabilizing specimens to identify bacteria and viruses, especially during diagnostic investigations.
To strengthen pandemic management, microbiology specimen collection and future preparedness for COVID-19 and other infectious diseases, international strategies for the regulation, evaluation, and use of digital technologies such as digital epidemiological surveillance, rapid case identification, interruption of community transmission, transport of viral specimen and future preparedness for COVID-19 and other infectious diseases must be aligned.
A variety of protein supplements have been and continue to be prescribed to improve viral stability. These are generally made up of balanced salt or saline solutions with a buffering ability to keep the pH close to neutral. While some laboratories collect, transport, and store samples for viral diagnosis, commercial preparations are often utilized and generally come with sterile swabs as part of a sample collection kit.
The overall growth of global virology specimen collection market comes from the united growth of virology transport media and nasopharyngeal sample.
The global market study on the virology specimen collection market is segmented into categories; Product type sample. These categories and their segment’s performance differ with different regions. There are segments like blood collection kits, specimen collection, viral transport media, and swabs based on product type.
Based on the sample, the segments are blood samples, nasopharyngeal samples, throat samples, cervical samples, oral samples and other samples. The services related to it are virology sample collection, laboratory testing and microbiology specimen collection.
The virology specimen collection market report tells that the virology transport media segment is likely to perform better than any other segment of product type categories. The reason behind the growth of this specific segment is the high number of blood donations having all around the world.
Also, the emergence of new pathogens is driving the force behind the sales of virology specimen collection and virology transport media. Consumers are getting aware about the global blood banks with the increasing number of cancer cases, which encourages them to donate blood.
The nasopharyngeal sample segment holds the most significant portion of the market share. The primary reason behind that is the fast detection of transmissible transfusion infection (TTIs) and the increased prevalence of HPV-related cancers (all cervical cancers) & human papillomavirus (HPV).
The transmissible infections led to nasopharyngeal samples more often in the healthcare and medical industry. Emerging trends in the virology specimen collection market also estimate that the nasopharyngeal samples are likely to witness the highest sales post the forecast period.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The market for virology specimen collection is highly consolidated. In the virology specimen collection market, the key players are Becton, Dickinson and Company (USA), Quidel Corporation (USA), Thermo Fisher Scientific Inc. (USA), Trinity Biotech (Ireland), and Titan Biotech Ltd. (India). These key players accounted for a combined majority market share in 2020.
There is fierce competition among Key players in the virology specimen collection market. Only major corporations can afford significant capital expenditures and high R&D and manufacturing costs. New entrants will face difficulties entering the virology specimen collection market due to this.
Along with these considerations comes the requirement for the application of digital technology, such as digital epidemiological surveillance, future preparation for COVID-19 and other infectious illnesses, pandemic management, community transmission interruption, and rapid case identification. As a result of these factors, the virology specimen collection market is expected to have numerous potential opportunities in future years.
The blood sample segment accounts for the highest growth rate.
Asia Pacific is predicted to experience the highest growth rate.
Need for alternative technologies for testing of virology samples is a major restraint.
The growth of the virology specimen collection market is likely to be USD 5.3 Billion by 2026.
The virology specimen collection market is likely to remain negative during the forecast period.
| Estimated Size, 2025 | USD 2,333.2 million |
|---|---|
| Projected Size, 2035 | USD 3,808.9 million |
| Value-based CAGR (2025 to 2035) | 5.0% |
| Market Value in 2021 | USD 2.6 Billion |
|---|---|
| Market Value in 2032 | USD 4.4 Billion |
| Device Market CAGR (2022 to 2032) | 5.2% |
Explore Life Science & Biotechnology Insights
View Reports
Virology Specimen Collection Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
